AMI Pharm focuses on developing safer solutions for the removal of unwanted fat for those seeking beauty enhancements.
Our leading pipeline, AYP-101, a Phase 3 clinical study for the improvement of submental fat has completed, with a planned lauch in 2026.
We found that the API of AYP-101 caused adipocyte-specific apoptosis and lipolysis, marking the first such finding in the world. With these goundbreaking findings, we started an audacious journey to develop the next generation of fat reduction treatments to meet the unmet needs in current cosmetic plastic surgery for fat reduction.
Through our efforts to develop a safe and stable injectable formulation of AYP-101 using its insolubale API, we successfully developed AYP-101 injection. We have also sucessfully completed non-clinical trials in accordance with ICH guidelines, as well as one Phase 1 clinical trial and two Phase 2 clinical trials.
We would like to take this great journey together with our partner.